Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) saw an upside of 4.70% to $1.23 after adding $0.06 on Wednesday. The 5-day average trading volume is 1,333,990 shares of the company’s common stock. It has gained $1.2599 in the past week and touched a new high 3 times within the past 5 days. An average of 1,683,012 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,604,133.
LXRX’s 1-month performance is -33.78% or -$0.6000 on its low of $1.0400 reached on 09/25/23. The company’s shares have touched a 52-week low of $1.04 and high of $3.79, with the stock’s rally to the 52-week high happening on 05/05/23. YTD, LXRX has lost -35.86% or -$0.6800 and has reached a new high 14 times. However, the current price is down -67.67% from the 52-week high price.
Valuation Metrics
LXRX stock has a beta of 1.26. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 731.80 while the price-to-book (PB) in the most recent quarter is 1.62.
Lexicon Pharmaceuticals Inc’s quick ratio for the period ended June 29 was 10.09, with the current ratio over the same period at 10.10. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.56, while the total debt to equity was 0.57. In terms of profitability, the gross margin trailing 12 months is -16.42%. The trailing 12-month EBITDA margin is -72182.01% while for the period ending June 29, Lexicon Pharmaceuticals Inc’s operating margin was -31557.60%. The firm’s gross profit as reported stood at $0.14 million against revenue of $0.14 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 45.23% to -$44.9 million, while revenue of -$31.93 million was 28.89% off the previous quarter. Analysts expected LXRX to announce -$0.17 per share in earnings in its latest quarter, but it posted -$0.22, representing a -29.40% surprise. EBITDA for the quarter stood at more than -$43.82 million. LXRX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 130.36 million, with total debt at $105.55 million. Shareholders hold equity totaling $244.93 million.
Let’s look briefly at Lexicon Pharmaceuticals Inc (LXRX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 26 September was 39.75% to suggest the stock is trending Neutral, with historical volatility in this time period at 101.69%.
The stock’s 5-day moving average is $1.1320, reflecting a +6.03% or $0.0700 change from its current price. LXRX is currently trading -35.26% above its 20-day SMA, -60.06% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -44.84% and SMA200 by-43.32%.
Stochastic %K and %D was 18.86% and 9.70% and the average true range (ATR) pointed at 0.0961. The RSI (14) points at 35.59%, while the 14-day stochastic is at 32.20% with the period’s ATR at 0.0982. The stock’s 9-day MACD Oscillator is pointing at -0.0311 and -0.1352 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Lexicon Pharmaceuticals Inc (NASDAQ: LXRX), Jefferies launched coverage with a Hold rating. Analysts offering their rating for LXRX stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate LXRX as a “sell,”, while 2 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 2 have offered a “buy” rating.
What is LXRX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $1.65 and a high of $10.00, with their median price target at $5.00. Looking at these predictions, the average price target given by analysts is for Lexicon Pharmaceuticals Inc (LXRX) stock is $5.55.
